Ruxolitinib for the Treatment of Acute Respiratory Distress Syndrome in Patients With COVID-19 Infection

Sponsor
Azienda USL Toscana Nord Ovest
Study ID
NCT04361903
Status
Unknown

Conditions

  • Severe Acute Respiratory Syndrome Coronavirus 2

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

It is an observational, cohort, retrospective, monocentric, non-profit study. The primary objective is to evaluate the efficacy and safety of ruxolitinib in acute respiratory distress syndrome in patients with SARS-CoV-2 COVID-19 with rapid deterioration of respiratory parameters in the last 12 hours.

Key Dates

Start date
Apr 25, 2020
Status verified
Apr 2020
Primary completion
May 24, 2020
Completion
May 31, 2020

Study Design

Enrollment
13 participants (estimated)

Arms

  • Arm: Patients treated with ruxolutinib
    SARS-CoV-2 COVID-19 patients with rapid worsening of respiratory parameters in the last 12 hours treated with ruxolutinib, dosage of at least 20 mg x 2 / day in the first 48 hours.

Primary Outcome Measure

Number of patients who avoid mechanical assisted ventilation in acute respiratory distress syndrome in patients with SARS-CoV-2 COVID-19 [ Time Frame: 15 days ]

Central Contacts